GlassScriptPhysician profile
Javeed Siddiqui
NPI 1770563967
$1,522,377.57
in general payments reported to CMS, 2019-2025
18 companies · $263K in 2025
The $263K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269K · 2020: $138K · 2021: $111K · 2022: $224K · 2023: $252K · 2024: $266K · 2025: $263K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $483K · Travel and Lodging: $146K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $67K · Consulting Fee: $62K · Food and Beverage: $22K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $482,602.50 |
| Travel and Lodging | $146,291.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $67,445.00 |
| Consulting Fee | $61,885.80 |
| Food and Beverage | $22,232.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795,705.06 | 2019-2025 | Mavyret, Avycaz, Dalvance |
| Merck Sharp & Dohme LLC | $252,762.87 | 2019-2025 | Capvaxive, Zerbaxa, Vaxneuvance |
| Shionogi INC | $136,437.43 | 2022-2025 | Fetroja |
| Allergan, INC. | $91,668.77 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $84,298.79 | 2021-2025 | Nuzyra |
| Biomerieux INC | $45,248.17 | 2021-2025 | Bact/Alert, Biofire Blood Culture Identification 2 (Bcid2) Panel, Filmarray Gastrointestinal (Gi) Panel |
| Cumberland Pharmaceuticals, INC. | $37,817.52 | 2020-2023 | Vibativ |
| Biofire Diagnostics, LLC | $30,458.90 | 2019-2025 | Biofire Respiratory Panel 2.1 |
| Emd Serono, INC. | $25,495.13 | 2020-2022 | |
| La Jolla Pharmaceutical Company | $18,623.65 | 2022-2025 | Zevtera, Xerava, Giapreza |
| Glaxosmithkline, LLC. | $3,581.84 | 2023-2025 | Brexafemme, Blujepa |
| Melinta Therapeutics, LLC | $125.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $51.42 | 2024 | Austedo Xr |
| Lilly USA, LLC | $28.83 | 2023 | Mounjaro |
| Vertical Pharmaceuticals, LLC | $23.81 | 2025 | Relexxii |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.86 | 2022 | |
| Lundbeck LLC | $16.86 | 2022 | |
| Amgen INC. | $15.66 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javeed Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.